VANCOUVER, BC / ACCESSWIRE / April 21, 2021 / Sativa Wellness Group Inc. (CSE:SWEL) ("Sativa Wellness" or the "Company") wishes to announce that the Company's subsidiary, PhytoVista Laboratories, has been granted accreditation to ISO/IEC 17025:2017 - General requirements for the competence of testing and calibration laboratories.
Accreditation for the testing of cannabinoids, has been granted by United Kingdom Accreditation Service (UKAS), the UK governments appointed National Accreditation Body. The accreditation process determines the technical competence and integrity of organisations such as those offering testing services.
ISO17025 accreditation offers the Company a competitive advantage in regulated markets where organisations are required to test with an accredited laboratory. This development also positions the Company well to take advantage of a growing international market and developing regulatory landscape. The Company plans to increase the scope of testing covered by accreditation and penetrate other areas of testing, whilst continuing to develop and expand cannabinoid testing capabilities.
The Company is in the process of extending the Phytovista testing services to its laboratory in Poland to service Europe and as part of that process intends to implement the ISO17025 standard there.
Geremy Thomas Executive Chairman says "This success supports the direction of the Sativa Wellness Group to be the gold standard in the testing industry, driving growth through providing trusted services".
The Directors of the Company accept responsibility for the contents of this announcement.
On behalf of the Board of Directors,
Neither the Canadian Securities Exchange nor its Market Regulator (as defined in the policies of the Canadian Securities Exchange) accept responsibility for the adequacy or accuracy of this release.
This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Sativa Wellnesses' control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" "plan is" or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur", "will be achieved" or "shortly". The forward-looking information and forward-looking statements contained herein include, but are not limited to information concerning the fact that ISO17025 accreditation offers the Company a competitive advantage, positions the Company well to take advantage of a growing international market and developing regulatory landscape, will increase the scope of testing covered by accreditation, allows the Company to penetrates other areas of testing, develop and expand its cannabinoid testing capabilities or will be able to achieve ISO17025 in Poland.
Although Sativa Wellness believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. In particular, there is no guarantee that the Company will be successful in increasing their scope of testing, penetrating other areas of testing or developing and expanding cannabinoid testing capabilities or achieve ISO17025 in Poland. The forward-looking information and forward-looking statements contained in this news release are made as of the date of this press release, and Sativa does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
SOURCE: Sativa Wellness Group Inc.